Your psychiatrist mentioned ketamine as a treatment option, but you associate ketamine with anesthesia or recreational use. How can it help depression? And what would treatment actually involve?
Ketamine therapy for depression works through the glutamate system—the brain’s most abundant excitatory neurotransmitter—rather than the serotonin pathways that traditional antidepressants target. This different mechanism explains why ketamine can provide relief even when multiple standard medications haven’t worked. Research shows that 65-70% of patients with treatment-resistant depression respond to ketamine therapy, with effects often observable within hours rather than weeks (Kryst et al., 2020).
Understanding how ketamine works, what the treatment process involves, and what results you might realistically expect helps you determine whether this approach makes sense for your situation.
How Ketamine Works Differently Than Traditional Antidepressants
When you take an SSRI or SNRI, the medication increases serotonin or norepinephrine levels in your brain. That increased neurotransmitter availability then triggers a slow cascade of changes over 6-8 weeks that eventually improve depression symptoms—if the treatment works at all.
Ketamine works through an entirely different mechanism. Rather than adjusting serotonin levels, ketamine modulates NMDA receptors, which control glutamate signaling in your brain. This glutamate modulation triggers rapid release of brain-derived neurotrophic factor (BDNF), a protein that promotes the formation of new neural connections—a process called synaptogenesis (Wilkinson et al., 2018).
Think of depression as having damaged the neural pathways your brain uses for mood regulation, motivation, and pleasure. Traditional antidepressants try to optimize the neurotransmitter levels flowing through those damaged pathways. Ketamine helps your brain build new pathways entirely—which explains both why it works for people whose existing pathways don’t respond to serotonin optimization, and why effects can appear so rapidly.
This mechanism also explains ketamine’s effectiveness for suicidal ideation. Research shows that a single IV ketamine infusion produces rapid reduction in suicidal thoughts within 4 hours, sustained for up to 7 days (Wilkinson et al., 2018). Traditional antidepressants can’t match this timeline because serotonin-based neuroplasticity takes weeks to develop.
At Allevate Health in Princeton, board-certified emergency medicine physicians with 18 years of medical practice experience have seen this rapid mechanism provide relief for patients who had struggled for months or years with treatments targeting serotonin systems alone.
What the Research Shows About Ketamine’s Effectiveness
The FDA approved esketamine (brand name SPRAVATO®) for treatment-resistant depression in 2019 based on clinical trials demonstrating statistically significant improvement compared to placebo. In the key approval study, 70% of patients with treatment-resistant depression showed clinically meaningful response to esketamine, with effect onset within 24 hours (Daly et al., 2019).
For IV ketamine therapy—which has been studied for depression longer than the FDA-approved nasal spray—meta-analyses show response rates of 65-70% in treatment-resistant depression (Kryst et al., 2020). These response rates are particularly significant because the patients studied had already failed multiple traditional antidepressant trials. Ketamine wasn’t working in treatment-naive patients—it was providing relief to people for whom standard approaches hadn’t been sufficient.
Repeated ketamine infusions produce sustained improvement. While a single infusion typically provides relief lasting several days to two weeks, a series of 6-8 infusions administered over 2-4 weeks produces longer-lasting benefits. Many patients experience sustained improvement for weeks or months following the initial series, with some requiring only occasional maintenance infusions to maintain remission (Kryst et al., 2020).
Results vary by individual—some patients experience dramatic improvement, others moderate relief, and some don’t respond adequately despite the generally high response rates. But for patients who have completed multiple adequate trials of traditional antidepressants without success, these response rates offer genuine hope that relief is possible through a different mechanism.
The Different Forms of Ketamine Treatment
Ketamine therapy for depression is available in three primary forms, each with distinct characteristics and advantages.
IV ketamine therapy involves receiving ketamine intravenously over 45 minutes in a medical setting. The medication is administered slowly, allowing doses to be adjusted based on your response. Most patients receive a series of 6 initial infusions over 2-4 weeks, typically twice per week initially. IV administration allows for precise dosing and immediate medical supervision. At Allevate Health in Princeton, IV infusions are provided in private, comfortable rooms with calming music and amenities designed to optimize the therapeutic experience while maintaining rigorous medical oversight.
SPRAVATO® (esketamine nasal spray) is the FDA-approved form of ketamine specifically indicated for treatment-resistant depression. Esketamine is a more potent form of ketamine, administered as a nasal spray in a certified medical facility. You self-administer the spray under medical supervision, then remain monitored for at least two hours. SPRAVATO® has the advantage of FDA approval and insurance coverage for patients who meet criteria—typically those who have failed at least two adequate antidepressant trials. The treatment protocol involves twice-weekly sessions for the first month, then weekly or biweekly maintenance.
Ketamine-assisted psychotherapy (KAP) combines ketamine infusions with therapeutic sessions before, during, and after the medication experience. The ketamine promotes neuroplasticity—creating a window where your brain is more receptive to forming new patterns—while psychotherapy helps guide that neuroplastic change in therapeutic directions. This integrated approach can be particularly effective for patients whose depression involves trauma, rigid thought patterns, or psychological factors that benefit from therapeutic processing.
Each approach works through the same glutamate mechanism but offers different practical advantages. IV ketamine provides dosing flexibility and established protocols. SPRAVATO® offers FDA approval and insurance coverage. KAP adds psychological integration that may enhance and extend benefits. At Allevate Health, our team helps determine which approach best fits your clinical needs, insurance situation, and treatment goals.
What to Expect During Ketamine Treatment
Understanding the actual treatment experience helps demystify ketamine therapy and reduces anxiety about trying something unfamiliar.
Before your first session, you’ll complete a comprehensive evaluation to assess whether ketamine is appropriate for your situation. This includes reviewing your treatment history, current medications, medical conditions, and treatment goals. You’ll receive specific preparation instructions: no solid foods or milk for at least 6 hours before treatment, clear liquids allowed until 2 hours before, and no benzodiazepines or narcotics on treatment days as these can interfere with ketamine’s effectiveness.
During IV ketamine infusions, you’ll recline comfortably in a private treatment room. The medication is administered slowly over 45 minutes through an IV line. Most patients are offered wireless Bluetooth headphones with carefully curated music, and eye shades to reduce visual stimulation and promote an inward-focused experience. A board-certified physician monitors you throughout the infusion.
The subjective experience varies. Some patients report feeling very relaxed or slightly disconnected from their immediate surroundings—a sensation often described as “floating” or “lightness.” These dissociative effects are generally well-tolerated and are part of the treatment mechanism. You remain conscious and can communicate if needed, but many patients prefer to relax quietly with minimal interaction during the infusion.
After the infusion ends, effects diminish rapidly. Within 15 minutes, your thinking typically returns to normal. You’ll rest in the treatment room under observation before being cleared to leave. You cannot drive yourself home after treatment—you’ll need someone to accompany you or arrange alternative transportation.
Most patients report feeling effects on their depression symptoms within hours to days after their first infusion, though the full benefit typically builds over the initial series of treatments. Each subsequent infusion in the initial series generally deepens and extends the relief.
Who Is—and Isn’t—a Good Candidate for Ketamine Therapy
Ketamine therapy works best for specific patient populations with particular presentations of depression.
Good candidates typically include patients with treatment-resistant depression who have completed at least two adequate trials of standard antidepressants without sufficient improvement. Ketamine is particularly effective for patients with significant anhedonia (inability to experience pleasure), severe cognitive symptoms like concentration difficulties, and those with acute suicidal ideation who need rapid symptom relief. Patients whose depression includes trauma components may benefit particularly from ketamine-assisted psychotherapy approaches.
Ketamine may not be appropriate for patients with active psychosis or a history of psychotic disorders, as ketamine can potentially trigger or worsen psychotic symptoms. Patients with uncontrolled high blood pressure, certain cardiac conditions, or active substance use disorders require careful evaluation and may need medical clearance before proceeding. Pregnancy is generally a contraindication to ketamine therapy.
Comprehensive evaluation by experienced providers determines candidacy based on your complete medical and psychiatric history. At Allevate Health in Princeton, our board-certified physicians assess whether ketamine therapy is appropriate for your specific situation during complimentary consultations. This evaluation includes reviewing your treatment history, current medical status, and determining which form of ketamine treatment—IV therapy, SPRAVATO®, or ketamine-assisted psychotherapy—best fits your needs.
Understanding Costs, Insurance, and Access
Treatment costs and insurance coverage vary significantly depending on which form of ketamine therapy you pursue.
SPRAVATO® is FDA-approved for treatment-resistant depression and is covered by most major insurance plans when you meet medical necessity criteria—typically requiring documented failure of at least two adequate antidepressant trials from different classes. Prior authorization is required, involving submission of your treatment history and current diagnosis. For patients meeting criteria, insurance coverage can make SPRAVATO® the most accessible option financially.
IV ketamine therapy for depression is considered off-label use—meaning the medication is FDA-approved, but not specifically for this indication. Most insurance plans do not cover off-label IV ketamine for depression. At Allevate Health, IV ketamine infusions for depression, anxiety, or PTSD cost $600 per session, with a recommended initial series of 6 infusions over 2-4 weeks. Payment plans are available through Advanced Care to make treatment more accessible.
Ketamine-assisted psychotherapy costs vary based on the combination of medical ketamine administration and psychotherapy sessions. This integrated approach typically isn’t covered by insurance but may offer the most comprehensive treatment for patients whose depression has significant psychological components.
Understanding costs upfront helps you make informed decisions about which approach to pursue and plan accordingly. During consultations at Allevate Health, our team discusses pricing transparently and helps identify whether you might qualify for insurance-covered SPRAVATO® or whether IV ketamine therapy or KAP might better serve your clinical needs despite the out-of-pocket cost.
Practical Considerations for Starting Ketamine Treatment
Several practical factors influence whether ketamine therapy fits into your life right now.
Time commitment: The initial series typically requires 6 sessions over 2-4 weeks, with each session lasting 1-2 hours including preparation and recovery time. You’ll need transportation home after each session. For working professionals in Princeton and central New Jersey, scheduling twice-weekly appointments for 2-3 weeks requires planning around work commitments.
Support system: Having someone available to transport you home after sessions is essential, as you cannot drive for several hours after treatment. Some patients arrange for family members to accompany them; others use ride services. Planning this logistics in advance prevents treatment delays.
Managing other medications: Most antidepressants and psychiatric medications can continue during ketamine therapy, but benzodiazepines and narcotics must be avoided on treatment days as they reduce ketamine’s effectiveness. If you currently take these medications regularly, your provider will discuss how to manage this safely.
Setting realistic expectations: Ketamine therapy shows high response rates, but response doesn’t always mean complete remission. Some patients experience dramatic improvement; others achieve meaningful but partial relief. Results vary by individual, and some patients don’t respond adequately despite the favorable statistics. Understanding that ketamine is a powerful tool—not a guaranteed cure—helps maintain realistic expectations while pursuing treatment.
What Happens After the Initial Treatment Series
Ketamine therapy typically doesn’t end after the initial 6-session series. Most patients require some form of ongoing treatment to maintain benefits.
Maintenance infusions are scheduled based on individual response patterns. Some patients need maintenance sessions every 2-4 weeks; others remain stable for months before requiring additional treatment. The maintenance schedule is determined by monitoring your symptoms—when you notice depression symptoms beginning to return, it’s typically time for a maintenance infusion. This personalized approach means your treatment frequency adjusts to your specific needs rather than following a rigid protocol.
Integration with ongoing care: Ketamine therapy typically works best as part of comprehensive treatment, not as standalone intervention. Most patients continue psychotherapy, maintain lifestyle practices supporting mental health, and may continue some psychiatric medications even while benefiting from ketamine. The ketamine provides rapid symptomatic relief and neuroplastic foundation, while other treatments help consolidate and extend those gains.
Long-term outcomes: Research on long-term ketamine treatment shows that sustained improvement is possible with appropriate maintenance. Some patients eventually taper off ketamine entirely while maintaining remission; others continue maintenance infusions as needed for years. The goal is always to use the minimum frequency of treatment necessary to maintain wellness rather than following a predetermined protocol regardless of response.
At Allevate Health in Princeton, our team works with you to determine optimal maintenance scheduling based on your symptom patterns and helps coordinate ketamine therapy with your other mental health care providers to ensure comprehensive, integrated treatment.
Moving Forward with Ketamine Therapy
If you’ve completed multiple adequate trials of traditional antidepressants without sufficient improvement, ketamine therapy offers a mechanistically different approach with evidence supporting its effectiveness in treatment-resistant depression. Understanding how ketamine works, what treatment involves, and what results are realistic helps you make informed decisions about whether to pursue this option.
Ketamine therapy isn’t appropriate for everyone, and not everyone who tries it responds adequately. But for patients whose depression hasn’t responded sufficiently to serotonin-targeted treatments, the glutamate mechanism ketamine targets provides genuine new possibilities for finding relief.
To learn more about ketamine therapy for treatment-resistant depression or to schedule a complimentary consultation to assess whether you’re an appropriate candidate, contact Allevate Health in Princeton, New Jersey at 640-252-9785 or visit allevatehealth.com. Our board-certified emergency medicine physicians provide comprehensive evaluations and can help determine whether IV ketamine therapy, FDA-approved SPRAVATO®, or ketamine-assisted psychotherapy best fits your clinical needs and practical situation.
References
Daly, E.J., Trivedi, M.H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A.R., Hough, D., Thase, M.E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W.J., Bitter, I., Blier, P., Shelton, R.C., Molero, P., Manji, H., Drevets, W.C., & Singh, J.B. (2019). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry, 76(9), 893-903. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2725252
Kryst, J., Kawalec, P., Mitoraj, A.M., Pilc, A., Lasoń, W., & Brzostek, T. (2020). Efficacy of repeated ketamine infusions for treatment-resistant depression: A meta-analysis. Canadian Journal of Psychiatry, 65(11), 731-742. https://journals.sagepub.com/doi/full/10.1177/0706743719897757
Wilkinson, S.T., Ballard, E.D., Bloch, M.H., Mathew, S.J., Murrough, J.W., Feder, A., Sos, P., Wang, G., Zarate, C.A., & Sanacora, G. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150-158. https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2017.17040472